Rockefeller Capital Management
TOVX icon

Rockefeller Capital Management’s Theriva Biologics TOVX Stock Holding History

Rockefeller Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed – – 3728
2022
Q4 		$0 Hold
1
– – ﹤0.01% 4211
2022
Q3 		$0 Hold
1
– – ﹤0.01% 4370
2022
Q2 		$0 Buy
+1
New +$57 ﹤0.01% 4390

Other funds holding TOVX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Rockefeller Capital Management's TOVX Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Theriva Biologics (TOVX) in Q1 2023, closing a stake of 1 share.

Rockefeller Capital Management first reported a position in TOVX in Q2 2022 and held it in 3 quarters. The position peaked at $0 in Q4 2022. 17 funds tracked by Wall St. Rank hold TOVX as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Theriva Biologics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 1 Theriva Biologics share in Q1 2023.
  • Rockefeller Capital Management first reported a position in Theriva Biologics in Q2 2022 and held it in 3 quarters.
  • Rockefeller Capital Management's Theriva Biologics position peaked at $0 in Q4 2022.
  • 17 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.